Abstract

The HER2/neu receptor is a protooncogene that is overexpressed in approximately 30% of human breast cancers. Therapy with a recombinant humanized monoclonal antibody to HER2/neu (Herceptin) has shown efficacy in large clinical trials, both as a single agent and also when used in combination with chemotherapeutic agents/drugs. However, only 15-20% of patients with HER2-overexpressing tumors will respond to this treatment, and responses appear to be limited to those tumors with the highest expression of HER2. Attempts to enhance the actions of Herceptin have been hampered by our limited knowledge of its mechanism of action. We have recently demonstrated that co-stimulation of natural killer (NK) cells with Herceptin-coated breast cancer cells and interleukin-12 results in the production of large quantities of interferon-gamma (IFN-g) and other immunomodulatory cytokines with anti-tumor actions. Based upon these findings, we have recently initiated an NCI-sponsored Phase I trial in which Herceptin is administered in combination with interleukin-12 to patients with HER2-overexpressing malignancies. This trial is based upon the theory that the host immune response to biologically relevant monoclonal antibodies may be significantly enhanced in the presence of interleukin-12.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000034-40
Application #
6404360
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1976-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
40
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Beversdorf, David Q; Carpenter, Allen L; Alexander, Jessica K et al. (2018) Influence of Serotonin Transporter SLC6A4 Genotype on the Effect of Psychosocial Stress on Cognitive Performance: An Exploratory Pilot Study. Cogn Behav Neurol 31:79-85
Tita, Alan T N; Lai, Yinglei; Landon, Mark B et al. (2017) Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes. Am J Perinatol 34:1464-1469
Criado, Kristen K; Sharp, William G; McCracken, Courtney E et al. (2017) Overweight and obese status in children with autism spectrum disorder and disruptive behavior. Autism :1362361316683888
Lee, Kyoung Suk; Lennie, Terry A; Yoon, Ju Young et al. (2017) Living Arrangements Modify the Relationship Between Depressive Symptoms and Self-care in Patients With Heart Failure. J Cardiovasc Nurs 32:171-179
Landon, Mark B; Grobman, William A; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network (2016) What We Have Learned About Trial of Labor After Cesarean Delivery from the Maternal-Fetal Medicine Units Cesarean Registry. Semin Perinatol 40:281-6
Blackwell, Sean C; Landon, Mark B; Mele, Lisa et al. (2016) Relationship Between Excessive Gestational Weight Gain and Neonatal Adiposity in Women With Mild Gestational Diabetes Mellitus. Obstet Gynecol 128:1325-1332
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Salazar, Ashley; Tolivaisa, Susan; Allard, Donna et al. (2016) What we have learned about best practices for recruitment and retention in multicenter pregnancy studies. Semin Perinatol 40:321-7
Harper, Lorie M; Mele, Lisa; Landon, Mark B et al. (2016) Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes. Obstet Gynecol 127:893-8
Alhurani, Abdullah S; Dekker, Rebecca L; Abed, Mona A et al. (2015) The association of co-morbid symptoms of depression and anxiety with all-cause mortality and cardiac rehospitalization in patients with heart failure. Psychosomatics 56:371-80

Showing the most recent 10 out of 426 publications